– Enable Injections, Inc. (“Enable”), a leader in wearable drug delivery technology, today announced an expanded partnership with Roche. 

– The collaboration leverages Enable’s expertise in the enFuse® platform to accelerate the development and commercialization of innovative treatment options.

EnFuse Technology: Revolutionizing Drug Delivery

The enFuse platform is a groundbreaking wearable device designed for:

• Subcutaneous Delivery of Large Volumes: Unlike traditional methods, enFuse delivers large volumes of medication subcutaneously, eliminating the need for intravenous (IV) administration.
• Simplified Treatment Experience: enFuse offers a simpler and potentially more comfortable injection experience for patients compared to IV treatments.

Roche Gains Exclusive Rights to Combine enFuse with Specific Molecules

Under the terms of the agreement, Roche receives a worldwide, exclusive license to develop and commercialize combinations of the enFuse technology with specific drugs from their portfolio. Enable will take responsibility for the clinical and commercial manufacturing and supply of the enFuse system.

“IV infusions can be inconvenient and time-consuming for both patients and providers. This is especially true when treating chronic disorders, which require longer-term treatment and frequent trips to the clinic,” said Mike Hooven, Chairman and CEO of Enable Injections. “enFuse was designed to overcome IV infusion shortcomings through fast, simple and convenient delivery, bringing efficiency and value to the entire spectrum of healthcare, including patients, providers, and payers, with the ability for at home self-administration.”

What You Should Know: 

– Vivalink, a frontrunner in digital healthcare solutions, today announced the launch of a comprehensive technology solution for Mobile Cardiac Telemetry (MCT) and Holter monitoring. 

– The innovative offering addresses the rising demand for efficient ambulatory ECG monitoring, streamlining deployment and enhancing patient care.

Efficiency with a Unified Approach

Vivalink’s solution integrates Remote Patient Monitoring (RPM) technologies and advanced arrhythmia detection algorithms. This unification offers significant advantages:

• Simplified Deployment: Partners can leverage a single solution for both MCT and Holter monitoring, reducing complexity and cost.
• Enhanced Patient Care: Streamlined workflows ensure faster diagnosis and treatment for patients with cardiac concerns.

Designed for Enhanced Patient Care

The solution boasts a range of features designed to optimize the ambulatory cardiac monitoring experience:

• Long-lasting Convenience: A reusable ECG patch with a 14-day rechargeable battery and 30-day data storage capacity minimizes patient burden.
• Seamless Data Transmission: A mobile gateway integrated with a patient app facilitates effortless data transmission and keeps patients engaged in their monitoring process.
• Advanced Arrhythmia Detection: The solution can identify over 15 common arrhythmias and ectopic beats, empowering clinicians with crucial insights.
• Clinician-Centric Design: A dedicated clinician portal allows for over-reading, annotation, and generation of customized final ECG reports tailored to specific needs.

“Bringing together cutting-edge technology and medical expertise, Vivalink’s turnkey technology solution is changing the landscape of ambulatory cardiac monitoring,” said Jiang Li, CEO of Vivalink. “Our integrated solution simplifies the deployment of remote cardiac monitoring services, offering a seamless implementation for our partners.”

What You Should Know: 

– Blue Earth Diagnostics, a Bracco company and leader in innovative PET radiopharmaceuticals, announced a data-sharing agreement with Siemens Healthineers. 

– This collaboration focuses on anonymized data from Blue Earth’s Phase 3 LIGHTHOUSE trial of POSLUMA® (flotufolastat F 18) injection, used for imaging prostate cancer.

Optimizing AI for Improved Prostate Cancer Detection

Siemens Healthineers will leverage the anonymized clinical data and images from the LIGHTHOUSE trial to enhance its AI-powered analytics for prostate cancer. This will lead to:

• More Precise Image Quantification: AI algorithms will be refined to provide more accurate measurement of prostate cancer lesions detected by POSLUMA PET scans.
• Enhanced Image Interpretation: Advanced AI tools will be developed to assist healthcare professionals in interpreting PET scans, potentially leading to earlier and more precise diagnoses.

About POSLUMA®

POSLUMA, previously known as 18F-rhPSMA-7.3, is a recently approved radiopharmaceutical for PET imaging of prostate cancer. It targets the Prostate-Specific Membrane Antigen (PSMA), a protein often overexpressed by prostate cancer cells. This targeted approach allows for more effective detection of prostate cancer compared to traditional imaging methods.

Details of the LIGHTHOUSE Trial

The LIGHTHOUSE trial was a large-scale clinical study involving over 350 men with newly diagnosed prostate cancer. It evaluated the safety and effectiveness of POSLUMA PET imaging in identifying prostate cancer lesions.

Blue Earth Diagnostics: A Leader in rhPSMA Technology

Blue Earth Diagnostics holds exclusive worldwide rights to the radiohybrid Prostate-Specific Membrane Antigen (rhPSMA) diagnostic imaging technology. This technology has the potential to revolutionize prostate cancer diagnosis and treatment.

“Blue Earth Diagnostics is committed to helping men with prostate cancer across the care continuum, and we recognize the importance of AI in advancing healthcare,” said David Gauden, D.Phil., Chief Executive Officer, Blue Earth Diagnostics. “AI-based algorithms have the potential to streamline the PET/CT analytical workflow for hospitals and imaging centers by efficiently providing physicians with information critical to patient management and care. Blue Earth Diagnostics has a long-standing relationship with Siemens Healthineers, a leading medical technology company pioneering breakthroughs in healthcare.”

What You Should Know: 

– Keith Jones has been appointed as the permanent chief information officer (CIO) at Cone Health after serving in an interim capacity since September. With over a decade of experience at Cone Health, Jones has been instrumental in spearheading initiatives to align with the organization’s strategic goals and enhance healthcare experiences.

– During his tenure, Jones played a pivotal role in developing Cone Health’s initial strategy for data warehousing, business intelligence, and analytics. He successfully led the implementation of Cone Health’s enterprise data warehouse framework and established an enterprise analytics function, laying the foundation for data-driven decision-making across the system.

Keith Jones Bio/Background

Jones’s expertise extends to digital health incubation and transformation, driving innovation aimed at improving patient care, provider experiences, and overall operational efficiency within Cone Health. He is known for his passionate advocacy for a metrics-driven approach, which has contributed to Cone Health’s leadership position in value-based care delivery.

Before joining Cone Health, Jones held key positions, including director of business intelligence at Europa Sports Products and director of information technology at Inmar Enterprises. He holds a Master of Healthcare Administration from Pfeiffer University and a bachelor’s degree in information systems/operations management from the University of North Carolina at Greensboro.

What You Should Know: 

– Paytient, the leading innovator in health plan affordability solutions, today announced the appointment of Joe Gabler as its Chief Growth Officer (CGO). 

– Mr. Gabler brings nearly two decades of experience in building successful companies and pioneering healthcare consumer payment solutions. He will play a pivotal role in driving Paytient’s expansion as the company forges strategic partnerships with leading employers, payers, and Pharmacy Benefit Managers (PBMs).

A Proven Track Record of Success

Mr. Gabler boasts an impressive career trajectory. He spent the first 13 years at SPS Commerce (SPSC), contributing to its transformation from a fledgling business into a powerhouse with a successful IPO and multi-billion dollar market valuation. During his tenure, he held diverse leadership positions encompassing operations, strategy, and growth management.

For the past six years, Mr. Gabler has focused on revolutionizing the healthcare benefits landscape. At Solutran (acquired by Optum), he spearheaded innovative consumer payment strategies. His leadership resulted in the creation of a market-leading payment network serving over half of the Medicare Advantage market, processing billions of dollars in annual consumer benefit payments.

Scaling Partnerships to Expand Healthcare Access

Paytient is a trusted partner to over 5,000 enterprise partners, impacting the lives of nearly 25 million individuals. With Joe Gabler at the helm of growth initiatives, Paytient aims to further scale its partnerships. This includes building relationships with mid-market employers, large commercial groups, prominent payers, and Medicare plan sponsors. The ultimate goal: making healthcare more accessible and affordable for millions more Americans in the coming years.

“The Medicare Prescription Payment Plan in 2025 means that smoothing out-of-pocket costs over time is becoming a standard of care for healthcare in the United States. Paytient is well positioned to serve as the leading platform giving Americans a better ability to access and afford care,” said Brian Whorley, Founder and CEO of Paytient. “As we prepare for the growth this will bring, Joe’s proven ability to scale teams and operations with winning cultures is a fantastic and critical addition to our leadership team.” 

What You Should Know: 

– Rad AI, a leader in generative AI for healthcare, announced today it has raised $50M in Series B financing, bridging its total capital raised to over $80M. 

– The round was led by Khosla Ventures, with participation from prominent investors including WiL (World Innovation Lab), ARTIS Ventures, OCV Partners, Kickstart Fund, and Gradient Ventures (Google’s AI-focused fund).

Revolutionizing Radiology Reporting

Rad AI’s solutions are already making waves in the healthcare industry. Used by over a third of US health systems and 9 of the 10 largest radiology practices, their technology saves physicians significant time and improves patient care.

Pioneering generative AI in healthcare since 2018, Rad AI automates report generation, allowing radiologists to customize reports with their own language and style. This frees them from the burden of dictation, a task that consumes 75% of their time, often for reports on over 100 patients daily.

Leading the Way in AI-powered Reporting

Today, Rad AI offers cutting-edge solutions like Rad AI Reporting, the industry’s leading AI-powered tool for radiology reporting workflow. Additionally, Rad AI Continuity simplifies patient follow-up, with adoption by many of the nation’s largest health systems. Combined, these solutions positively impact nearly 50 million patients annually.

Reduced Burnout, Improved Care

Rad AI’s AI models take over repetitive tasks like dictation and follow-up management. This frees up valuable time for physicians, reduces burnout, and allows them to focus on what matters most – providing exceptional patient care. Hospitals using Rad AI’s solutions have seen:

• A dramatic increase (from 30% to over 85%) in patient follow-up rates for critical findings, ensuring timely diagnoses and treatment, especially for new cancers.
• Doubled report creation speed, often with a 90% reduction in dictated words, leading to less fatigue and burnout for radiologists.
• A near 50% reduction in report errors for complex cases, ultimately improving the quality of care provided.

“At Rad AI, we’ve built the most widely adopted generative AI solutions in healthcare, saving physicians time and improving patient care. Rad AI has become a mission-critical part of health system workflows over the past five years. This strategic funding round further cements our position as the leading AI-driven workflow platform in healthcare.”-Doktor Gurson, co-founder and CEO of Rad AI

What You Should Know: 

– BrightInsight, Inc., a provider of compliant digital health solutions, today announced its collaboration with Google Cloud to leverage cutting-edge generative AI (gen AI) technology. 

– The enhanced partnership aims to optimize BrightInsight’s research and development efforts and significantly enhance its Disease Management Solution for both patients and healthcare providers.

Addressing Challenges in the Patient Journey

Across various therapeutic areas, patients often face hurdles throughout their treatment journey. These challenges include navigating access and financial barriers, transitioning between treatment options, managing complex treatment schedules, and tracking symptoms and treatment effectiveness.

Improving Patient Education and Support with AI

BrightInsight is tackling these challenges head-on by integrating Google Cloud’s Gemini and MedLM gen AI models within its Disease Management Solution. This integration offers several key benefits:

• AI-powered Chatbot: A chatbot powered by Gemini provides patients with improved access to approved educational content. Patients can receive immediate answers to their questions by leveraging a vast library of clinically validated information, eliminating the need to search through multiple documents.
• Enhanced Patient Support: The chatbot also serves as a first-line support system, offering quick and specific answers to patient inquiries regarding app usage.

Optimizing BrightInsight’s Internal Operations

BrightInsight is also utilizing Gemini Code Assist to streamline its internal R&D processes in three ways:

• Developing and Operating Google Cloud Components: Gemini Code Assist helps BrightInsight’s development team work more efficiently when building and managing Google Cloud components.
• Improved Troubleshooting: The technology assists in troubleshooting issues more effectively, saving valuable time and resources.
• Enhanced Analytics and Insights: By leveraging gen AI, BrightInsight can generate more insightful data analytics for its customers.

Leveraging MedLM for Improved Patient Data Management

Furthermore, BrightInsight is utilizing MedLM to summarize, analyze, and make patient data from companion apps more usable for clinicians. This allows for more impactful and data-driven conversations between patients and providers. For example, healthcare professionals can quickly identify missed medication doses or abnormal readings, enabling them to have focused discussions with their patients.

Prioritizing Security and Compliance

As BrightInsight advances its gen AI-based solutions, the company remains steadfastly committed to responsible implementation. Their platform and Disease Management Solution adhere to the highest security, privacy, and compliance standards, achieving certifications against global regulations. The integration of AI will follow the same rigorous approach, ensuring patient data protection.

“We have invested a lot in building best-in-class technology and hiring top engineering talent,” said Ashish Agrawal, chief technology officer, BrightInsight. “Partnering with Google Cloud and leveraging its AI technologies will enable BrightInsight to supercharge its solutions to achieve our vision of transforming patient outcomes through digital technologies.”

What You Should Know: 

– A new study by Arcadia, a healthcare data platform, reveals a paradox within the industry: while 80% of healthcare leaders believe most of their data is accurate, a staggering 47% remains underutilized for critical clinical and business decisions. 

– The report findings uncover a significant challenge – the immense potential of healthcare data remains largely untapped despite the rise of artificial intelligence (AI).

Healthcare Data: A Treasure Trove of Untapped Potential

The study, conducted in partnership with the Healthcare Information and Management Systems Society (HIMSS), surveyed healthcare leaders across various institutions. Here are some of the key takeaways:

• Vast Underutilization of Data: While 80% of healthcare leaders believe most of their data is accurate, a staggering 47% remains underutilized for clinical and business decision-making. 
• Data’s Potential for Improved Care: More than half of healthcare leaders acknowledge the power of data in enhancing care quality. Nearly a quarter view data as essential for patient engagement and care management strategies. Additionally, 28% recognize the role of data platforms in improving health outcomes and patient satisfaction. These findings underscore the critical role of data analytics in the transition towards value-based care models.
• Actionable Insights for Efficiency and Productivity: A significant majority (95%) of healthcare leaders see the potential for data and analytics to improve clinician productivity. Furthermore, 30% believe data platforms can generate cost savings through optimized resource allocation and workforce management, while 25% acknowledge their role in better decision-making. In a healthcare landscape facing workforce shortages, burnout, and rising costs, data can be a powerful tool for optimizing operations and delivering quality care with fewer resources.
• Embracing AI for Innovation: The future of healthcare data lies in artificial intelligence (AI). The study revealed that 84% of leaders have plans to integrate AI, machine learning, or large language models with their data platforms. Additionally, 55% plan to leverage unstructured data (images, audio, PDFs) to extract valuable insights and streamline workflows. For instance, Arcadia’s AI-powered clinical co-pilot, Arcadia SageAI™, has demonstrably reduced patient appointment preparation time by over 20%. 
• Bridging the Usability Gap: While data holds immense potential, healthcare leaders acknowledge challenges in data utilization. Enhancing data literacy (58%), implementing AI solutions (47%), and addressing productivity concerns (34%) were identified as key priorities for improving data usability. Interestingly, 76% of large healthcare organizations emphasized the need for comprehensive enterprise data solutions, highlighting the growing need to unify disparate data sources for holistic insights.
• Real-Time Data for Real-Time Care: Although 61% of organizations refresh data daily for business intelligence, that figure dips to 32% for AI model development. Similarly, only a fraction leverage daily data for tasks like identifying care gaps and patient stratification.  Real-time data activation equips care teams with the most current patient information, ensuring informed decision-making.

“Our findings show that healthcare leaders view data analytics platforms as critical tools to confront growing workforce shortages, financial pressures, and the shift towards value-based care,” said Michael Meucci, President and CEO of Arcadia. “Investing in a strong data analytics platform can further transform these challenges into opportunities and progress towards a more efficient and effective healthcare system.”

What You Should Know: 

– ARC Innovation, the innovation arm of Sheba Medical Center, Israel’s leading medical center and a six-time Newsweek World’s Best Hospital awardee, today announced its participation in the Trustworthy & Responsible AI Network (TRAIN). 

– The consortium brings together healthcare luminaries dedicated to integrating responsible AI practices effectively within the healthcare landscape.

AI Transforming Healthcare Landscape

AI is rapidly transforming healthcare, impacting everything from patient education and support to diagnostics, precision medicine, clinical decision-making, and drug development. However, as AI becomes increasingly pervasive, so too does the need for robust guidelines and standards to ensure its responsible and impactful use.

TRAIN: A Collaborative Effort for Responsible AI Implementation

The Trustworthy & Responsible AI Network (TRAIN) was unveiled at the recent HIMSS Global Health Conference. This consortium unites leading academic healthcare institutions, health systems, and technology providers such as Duke Health, Vanderbilt University Medical Center, Microsoft, and ARC Innovation at Sheba Medical Center. By working collaboratively, TRAIN seeks to establish a framework for the responsible use of AI in healthcare, ensuring patient safety, ethical considerations, and optimal clinical outcomes.

“AI is a transforming force within healthcare, with new solutions developed daily, bringing considerable benefits to every aspect of health,” said Professor Eyal Zimlichman, MD, Chief Innovation and Transformation Officer at Sheba Medical Center and Founder and Director of ARC Innovation. “In order to effectively implement AI technologies, innovation must be balanced with responsibility and trust. AI cannot be implemented without safeguards, and only through rigorous quality and safety controls can health systems adopt these new solutions.”

TRAIN members will collaborate to enhance the quality and reliability of AI in healthcare by sharing best practices, enabling registration of AI used for clinical care through a secure online portal, and providing resources for assessing outcomes of AI implementation, while ensuring privacy preservation throughout the deployment phases. The consortium will also support the establishment of a federated national AI outcomes registry to document real-world results concerning algorithm effectiveness, safety, and refinement.

What You Should Know: 

– Steward Health Care, the nation’s largest physician-led hospital operator, announced today that it has filed for Chapter 11 bankruptcy protection in the U.S. Bankruptcy Court for the Southern District of Texas.

– Steward assures patients and the broader community that day-to-day operations will continue uninterrupted throughout the Chapter 11 process. Hospitals, medical centers, and physician offices will remain open and fully functional. The company’s commitment to its employees also remains unchanged.

Seeking Financial Restructuring to Ensure Continued Care

Steward cited the Chapter 11 filing as a necessary step to ensure the continued delivery of essential healthcare services to its communities. The company has secured initial debtor-in-possession financing of $75 million from Medical Properties Trust, with the potential for an additional $225 million upon meeting specific conditions.

A Multifaceted Challenge

Steward identified several key factors contributing to its financial difficulties:

• Insufficient Reimbursement: Declining government insurance reimbursements have strained the company’s finances.
• Rising Costs: Steward faces escalating labor costs, material expenses, and operational overhead due to inflation.
• Lingering Pandemic Effects: The ongoing COVID-19 pandemic continues to impact Steward’s operations.

A Commitment to a Sustainable Future

Steward expressed its intention to navigate the Chapter 11 process swiftly, aiming for a long-term and financially stable future. The company has enlisted legal counsel, financial advisors, and investment banking services to guide the restructuring efforts.

“Steward Health Care has done everything in its power to operate successfully in a highly challenging health care environment. Filing for Chapter 11 restructuring is in the best interests of our patients, physicians, employees, and communities at this time,” said Dr. Ralph de la Torre, Chief Executive Officer of Steward. “In the past several months we have secured bridge financing and progressed the sale of our Stewardship Health business in order to help stabilize operations at all of our hospitals. With the delay in closing of the Stewardship Health transaction, Steward was forced to seek alternative methods of bridging its operations. With the additional financing in this process, we are confident that we will keep hospitals open, supplied, and operating so that our care of our patients and our employees is maintained. By working collaboratively with stakeholders in this court-supervised controlled environment, and having the benefit of our earlier strategic efforts, Steward will be better positioned to responsibly transition ownership of its Massachusetts-based hospitals, keep all of its hospitals open to treat patients, and ensure the continued care and service of our patients and our communities.”

What You Should Know: 

– DeepScribe, an innovator in ambient AI documentation for healthcare, announced the appointment of Dr. Dean Dalili, MD, MHCM, as its new Chief Medical Officer (CMO). 

– Dr. Dalili brings a wealth of experience to DeepScribe, poised to play a pivotal role in shaping the company’s clinical strategy and advancing its mission to revolutionize healthcare documentation.

Guiding DeepScribe’s Clinical Leadership

As CMO, Dr. Dalili will spearhead DeepScribe’s clinical strategy, focusing on three key areas:

• Enhancing Enterprise-Grade AI: Dr. Dalili’s expertise will be instrumental in refining DeepScribe’s AI technology, ensuring it delivers the highest standards of accuracy and clinical relevance.
• Building Strategic Partnerships: Leveraging his extensive network, Dr. Dalili will foster critical partnerships with healthcare organizations to facilitate widespread adoption of DeepScribe’s solutions.
• Driving Industry Impact: Dr. Dalili’s leadership will propel DeepScribe’s mission to transform healthcare documentation and improve patient care delivery.

Dr. Dalili Bio/Background

Dr. Dalili boasts an impressive two-decade career spanning clinical practice, academia, healthcare policy, and industry leadership. Prior to joining DeepScribe, he served as President of Market Operations at DispatchHealth, a tech-enabled healthcare startup, where he spearheaded operational excellence. He also held executive positions at Envision Healthcare and SCP Health, overseeing physician networks across 800 hospitals and health systems. Throughout his career, Dr. Dalili has consistently demonstrated success in population health management, improving clinical quality, and reducing healthcare costs.

"We are thrilled to welcome Dr. Dalili to our executive team," said Akilesh Bapu, CEO and Co-Founder of DeepScribe. "His extensive experience as a physician leader and his track record of driving healthcare innovation will be invaluable as we work to transform medical documentation and improve patient outcomes. With Dr. Dalili's guidance, we anticipate accelerating our product development, ensuring the highest standards of clinical accuracy, and delivering even greater value to our healthcare partners."

What You Should Know: 

– GE HealthCare announced the unveiling of SIGNA MAGNUS, a revolutionary head-only magnetic resonance imaging (MRI) scanner. 

– This FDA 510(k) pending technology holds immense promise for unlocking new frontiers in neuroscience research, a field previously limited by the capabilities of conventional whole-body MRI systems.

New Hope for Neurological Disorders

Neurological disorders, including Alzheimer’s disease, affect a staggering 43% of the global population [ii]. However, current MRI technology can only diagnose a fraction of these conditions. SIGNA MAGNUS represents a significant leap forward, offering researchers a powerful tool to investigate the complexities of the brain in unprecedented detail.

Designed for Neuroscientific Breakthroughs

GE HealthCare designed SIGNA MAGNUS specifically for neurological and oncological research. This state-of-the-art scanner boasts the following features:

• Superior Gradient Performance: HyperG gradient technology with 300 mT/m and 750 T/m/s enables the detection of finer details previously invisible to MRI.
• Advanced Techniques: Pushes the boundaries of anatomical, diffusion, and functional imaging techniques, further enhanced by GE HealthCare’s latest deep learning algorithms.
• Unveiling New Biomarkers: Offers vast potential for uncovering new parameters and biomarkers to advance diagnosis and treatment of complex brain diseases.
• Exceptional Diffusion Performance: Innovative asymmetric gradient design allows for high B-value diffusion with short echo times, providing a deeper understanding of neural architecture.
• Cost-Effective Upgrade Path: Many existing GE HealthCare 3.0T systems can be upgraded to SIGNA MAGNUS, minimizing capital expenditure for research institutions.

Collaboration for Innovation

In March 2024, Brigham and Women’s Hospital, a leading research institution, became the first to install the investigational SIGNA MAGNUS system. This collaboration between GE HealthCare and Brigham’s research team will be instrumental in spearheading cutting-edge neuro MRI research.

“With SIGNA MAGNUS, we are not just exploring the possibility of providing the tool; we are setting new benchmarks in medical research and future clinical patient care.” said Kelly Londy, CEO, MR GE HealthCare. “This innovation underscores our commitment to R&D and our collaborations with academia, pushing the boundaries of what’s possible in MR imaging. The potential impact of SIGNA MAGNUS on patient outcomes and our understanding of the human brain is profound.”

What You Should Know: 

– OverT Bio, a data-driven biotech company focused on unlocking the curative potential of cell therapies for solid tumors raises $16M in seed funding round. Co-led by ARTIS Ventures and Wing VC, the round saw participation from a distinguished group of investors including Fusion Fund, OMX Ventures, Alexandria Venture Investments, Gaingels, Civilization Ventures, Hawktail, and the Cancer Research Institute.

– The investment will fuel the company’s mission to develop more durable and effective cell therapies, offering new hope for patients battling advanced cancers.

A Data-Driven Approach to Cell Therapy Innovation

Founded in 2022 by Dr. Mat Legut and Dr. Neville Sanjana, OverT has pioneered new pooled functional screening and synthetic genomics platforms (OverTarget™ and OverTCR™) to develop next-generation engineered immune cells. OverT Bio takes a unique approach to cell therapy, leveraging a patient’s own immune response to discover novel cancer targets. The company’s groundbreaking technology scans the entire human genome, identifying new avenues to equip cell therapies with enhanced capabilities to combat and destroy cancer cells.

OverT Bio’s Pioneering Technologies:

• Massively Parallel Genetic Screening: This technology identifies the most effective genetic modifications to endow immune cells with potent anti-cancer properties.
• Single-Cell Multiomics: This platform provides a comprehensive view of individual cells within the tumor microenvironment, revealing critical insights for therapy development.
• Synthetic Biology Techniques: OverT Bio utilizes synthetic biology to engineer next-generation cell therapies with superior efficacy.

OverT Bio’s core platform represents a paradigm shift in cell therapy development. It systematically analyzes every gene in the human genome to discover the optimal genetic modifications for arming immune cells with the ability to recognize and eliminate cancer.

Strong Leadership and Scientific Foundation

OverT Bio boasts a seasoned leadership team with extensive expertise in cell therapy and immunology. Co-founder and CEO, Dr. Mat Legut, brings a proven track record of translating scientific discoveries into life-saving treatments. Co-founder, Dr. Neville Sanjana, is a renowned researcher at the New York Genome Center and NYU, and a pioneer in CRISPR technology and high-throughput functional genomics.

“Cell therapies have shown, at least in blood cancers, that we can aim to completely cure patients that have even the most advanced diseases rather than just prolong their survival,” said Dr. Mat Legut, co-founder and CEO of OverT. “With OverT’s ability to rapidly screen and engineer thousands of genes, we are building next-generation therapies to cure advanced cancers of the solid tissues.”

Human surgery training has used the classical approach of dissections of bodies and presence in live surgery for a long time. These means offer truly priceless opportunities to learn but multiple problems lie in accessibility, interactivity, and safety. AR has started a new era in surgical training through its affordability, interactivity, and safety. However, there still exists a need for proof regarding its effectiveness and  the possibility of any negative effects. In this article, we examine how to apply AR in the realm of surgical training and simulation and notice how it may be able to revolutionize the process.

Enhanced Visualization 

One of the main privileges of AR in surgical instruction is that it serves to offer visualization that is upgraded. Contrary to traditional methods that only use static pictures or physical models, AR displays anatomical data such as organs and tissues just as they are in a real-life surgical environment.

The use of advanced medical software gives the trainees an unsurpassed observation of the complex anatomy connections. Consequently, it boosts the spatial awareness and the depth perception of the trainees. Trainees can have practical experience as they learn to discern between the various anatomical structures and locate them in their spatial relations, being critical to surgical precision.

Interactive Learning

AR promotes training that consists of two-way communication with the trainee, instead of sheltering them from physical experience. By using AR in simulation surgery, trainees can improve their skills by practicing surgical procedures in a face-to-face environment and getting automated feedback on their moves and operations.

This method of errata practice is beneficial for the trainees because they will be able to hone their skills, know their weak spots, and learn from their mistakes. Not only does AR promote a better way of learning but it also improves comprehension as it stimulates them to use their brains and body as if they were doing the procedures themselves. Hence, this ensures that trainees are mentally ready to overcome real surgical uncertain situations.

Real-time Guidance 

The instrumentation AR imparts during surgery is the real-time orientation and sighting for surgeons which prompt decision making and navigation. Implementation AR with an overlay of instructions and anatomic annotations to the surgeon’s field of view will provide step by step guidance helping the doctor to perform each step of their procedure.

Receiving instant feedback upgrades the situational awareness level and reduces the chances of mistakes, particularly in complicated surgeries where every action requires a lot of thinking. A surgeon would obtain guidance through AR means and do his/her task with full confidence and accuracy, the second important expression that will lead to better results.

Remote Training Opportunities

AR has the potential to shift the paradigm of remote surgical education by nullifying the spatial constraints and connecting people to the difficult operation side of the specialty. The trainer might similarly mentor junior surgeons remotely with the AR tools available to gain a perspective and get recommendations instantly. Through this interdisciplinary approach not only the knowledge transfer is facilitated but also a community spirit is aroused among participants and trainers. In fact, AR training will help trainees learn at the pace that they are comfortable with for the issues to register in their heads for in-depth understanding and outstanding performance.

Endnote

Along with the advantages brought by AR in trained surgery, it comes with the baggage of challenges that require to be solved to be able to obtain the application’s full potential. Cost, real technical complexity, and training protocols, standardized for all, are the top barriers in the way to wide AR use in surgical training.

Nonetheless, research and development proceed in this direction to avoid a rise of the above-mentioned hindrances and increase the use of AR in surgery training. Technology without a doubt will move on and become more and more advanced. This will lead to the creation of new and more demanding AR-related innovations in the field of AR-driven surgical education, radically impacting the mode of training and preparation for the operating room.

What You Should Know:

– Harnessing the power of AI for healthcare just got simpler. NVIDIA announced the integration of NVIDIA NIM, a collection of cloud-native AI microservices, with Amazon Web Services (AWS). 

– The strategic collaboration empowers developers to leverage pre-trained AI models for drug discovery, medical imaging analysis, and genomics research – all accessible through user-friendly APIs.

Streamlined Access to Powerful AI Tools

NIM integrates seamlessly with popular AWS services like SageMaker (for machine learning model development) and ParallelCluster (for high-performance computing). Additionally, AWS HealthOmics, a specialized service for biological data analysis, can orchestrate NIM workflows. This integration simplifies the process of deploying cutting-edge AI models for healthcare and life sciences companies already using the AWS cloud infrastructure.

Benefits of NVIDIA NIM on AWS

• Faster Development: Researchers can bypass complex model development and packaging, accelerating the deployment of generative AI solutions.
• Multimodal Workflows: NIM facilitates the creation of workflows combining AI models from various sources, like protein sequences, medical images, and patient records.
• Enhanced Drug Discovery: BioNeMo, a foundation for AI models in drug discovery, is included in NIM. Companies like Amgen are already utilizing BioNeMo to train protein design models.

Real-World Examples of Success

• A-Alpha Bio: This company developing protein interaction prediction tools saw a 10x speedup by utilizing BioNeMo models optimized for NVIDIA GPUs on AWS.
• Agilent: This life sciences leader used NVIDIA Parabricks, a genomics analysis tool within NIM, to significantly improve processing speeds for variant calling workflows.

Beyond Drug Discovery and Genomics

NIM offers more than just scientific applications. It also includes:

• Large Language Models: These powerful language processing tools can be used to create conversational AI healthcare assistants for patient education and clinician support.
• Visual Generative AI: This technology allows for the development of digital avatars and chatbots for a more engaging user experience.